Our Pipeline
Our Pipeline
Based on the data obtained from (1) biodistribution studies of MEVs following different routes of administration in vivo (oral, respiratory, intranasal, topical-ocular, intravenous, intramuscular), and (2) functional data on the delivery and expression of different payloads and modalities, AGS has identified a number of Verticals or focus areas, namely: Ophthalmology, Bowel diseases, Vaccines, Gene Therapy, CNS disorders, and Respiratory diseases.
verticals
Verticals serve to structure and focus internal research, external collaborations, and further development work.
Each Vertical represents a somewhat homogenous biological system within the body: a limited number of organs and tissues, as well as specific morphological and physiological determinants and responses, specific biological barriers and levels of exposure, tolerance, and sensibility.
Each Vertical can be efficiently effected by a specific route of administration :
- Ophthalmology, by suprachoroidal injection or by drop instillation
- Bowel diseases, by oral administration
- Vaccines, by either oral-intestinal administration or by intramuscular administration
- Gene Therapy, by various administration routes
- CNS disorders, by intranasal administration
- Respiratory diseases, by intratracheal administration or nebulization
E
R
T
I
C
A
L
S
VERTICALS
PoC Completed
Disease Relevant
Animal Models
Regulatory
PreClinical
IND
Enabling
Partner
- Treatment of NV (neovascularization), including wAMD (wet age-related macular degeneration)
- Suprachoroidal injection or Topical administration (eye drops) breakthrough
- Payload : anti-angiogenic molecule
- Target tissue : choroid and retinal cells
- Treatment of IBD (inflammatory bowel disease)
- Oral administration (non-systemic) breakthrough
- Payload : modulator / ligand of endosomal TLR9
- Target tissue : enterocytes, intestinal resident macrophages
AGS supports the view that, with so many routes of administration at hand, and the body having so many entry doors, forward drug development might not need to be limited and primarily focused on the intravenous route of administration, which exposes the entire body to the putative drug and, therefore, to undesired and eventually systemic side effects, and which presents so many relevant intrinsic obstacles, such as the first-pass metabolism in the liver, the blood-brain barrier to access the brain, the filtration in the kidneys, among other.
The use of Verticals is a gateway to simplify and expedite clinical development of drug candidates.
AGS products consist of a highly specific payload encapsulated inside a generic MEV.
Whatever the nature of the payload, a MEV traveling through a particular route of administrition (whether the olfactory tract in the brain, the digestive tract, the airways, or the eye) remains a samely generic MEV.
Such MEV will display a specific pattern of tolerance, and biological interaction with the surrounding tissues that is expected to be : (1) particular to each route of administration, and (2) independent from the payload.
The choice of AGS’ initial internal pipeline is guided by four major objectives:
Loaded MEVs as Therapeutic products
(lungs, spleen, liver,..)
(eyes, naso-buccal, urogenital,..)
_360pix.png)
_1.jpg)
